Expert Interview
Discussing recent updates from EHA on menin inhibitors, including DSP-5336, JNJ-6617 in combo with Ven/Aza in r/r AML, and revumenib with the same combo but in newly diagnosed AML.
Ticker(s): JNJ, SNDX, KURAInstitution: Yale
- Assistant Professor of Medicine (Hematology) at Yale.
- Focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
- Participated in the K12 Calabresi Immuno-Oncology Training Program and has participated in several clinical trials aimed at improving the outcomes of patients with AML and MDS.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
